The Relative Strength (RS) Rating for Amgen climbed into a new percentile Wednesday, as it got a lift from 63 to 78.
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Amgen can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Amgen is building a consolidation with a 346.85 entry. See if it can break out in volume at least 40% higher than normal.
The company showed 13% EPS growth last quarter. Revenue gains came in at 11%.
Amgen holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
